Комитетът препоръчва на Intelence да бъде издадено разрешение за употреба.
This indication is based on the results of two 24-week studies of Intelence taken in combination with other anti-HIV medicines including darunavir boosted with ritonavir, which were carried out in patients with virus that was not responding to NNRTIs or protease inhibitors.